Terumo Corp is primarily active in the healthcare industry.

The main competitors of Terumo Corp in the market include Becton, Dickinson and Company (BD), Johnson & Johnson, and Medtronic. These companies compete with Terumo Corp primarily in the field of medical devices and healthcare products. However, Terumo Corp differentiates itself through its innovative product offerings, strong global presence, and cutting-edge technologies. Despite facing competition from these industry leaders, Terumo Corp has established a strong market position and continues to strive for excellence in providing quality healthcare solutions.

Terumo Corp. is a leading global medical device company specializing in the development and manufacturing of medical equipment and supplies. Founded in 1921 in Japan, Terumo has a rich history of innovation and growth. The company initially focused on the production of clinical thermometers and expanded over the years to produce a wide range of medical devices, including catheters, syringes, and cardiovascular systems. Today, Terumo Corp. is recognized for its expertise in areas such as cardiac and vascular surgeries, infusion therapy, and blood management. With a commitment to improving patient outcomes, Terumo continues to advance medical technology and provide innovative solutions for healthcare professionals worldwide.

Terumo Corp, a leading healthcare solutions company, has achieved several significant milestones. With a history spanning over 100 years, Terumo Corp has consistently demonstrated innovation and growth. Some notable achievements include the development of the world's first hollow fiber oxygenator and the creation of advanced interventional systems like the Radial Artery Approach Kit. Terumo Corp has also expanded globally, establishing a strong presence in various markets and collaborating with healthcare providers worldwide. These milestones showcase Terumo Corp's commitment to improving patient care and further solidify its position as a leader in the healthcare industry.

Terumo Corp is primarily present in Japan, where it is headquartered. In addition to its domestic market, Terumo Corp has a strong presence in various countries and regions around the world. The company has established subsidiaries and affiliates in the United States, Europe, Asia-Pacific, the Middle East, and Latin America. Terumo Corp's global footprint enables it to cater to the healthcare needs of a diverse consumer base, making it a leading player in the global medical devices industry.

Terumo Corp represents values and a corporate philosophy centered around improving patient care and contributing to society. With a commitment to innovation, the company strives to provide high-quality medical products and services. Terumo Corp emphasizes integrity, teamwork, and continuous improvement in its operations. By leveraging its expertise in medical technology, the company aims to tackle healthcare challenges and enhance the well-being of individuals worldwide. Terumo Corp's dedication to patient-centric healthcare solutions and its focus on ethical practices make it a trusted leader in the medical industry.

Analysts currently set an average price target of 3 115,37 JPY for the Terumo stock (median: 3 238,50 JPY), implying +18,7 % versus the latest price. The consensus is based on 20 analyst ratings.

Terumo Analyytikkojen kursstavoitteet 2026

20 analysts currently rate the Terumo stock: 16 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Terumo to generate revenue of 1,12 T JPY and earnings per share of 91,25 JPY.

Terumo Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Terumo share trades at 14,21 EUR (2 623,50 JPY).

The Terumo share (4543.T) is listed on 5 stock exchanges, including: Frankfurt (TUO.F), München (TUO.MU), Düsseldorf (TUO.DU).

The Terumo Corporation is a global company specializing in the development, manufacturing, and marketing of medical technology products. The company is headquartered in Tokyo, Japan and operates worldwide in the fields of cardiology, oncology, radiology, endoscopy, diabetes management, and blood management. One of the core elements of Terumo's business model is continuous research and development of new products. The company invests continuously in the development of medical devices to bring the latest technologies to market and drive innovation. An example of this is the Ultimaster-TF, a medical device for the treatment of heart diseases that is equipped with a special coating for longer-lasting effects and improved treatment efficiency. Terumo also operates an extensive distribution and marketing network to ensure its products are available worldwide. The company collaborates with local partners in various countries and leverages existing networks to sell its products. Terumo also maintains direct business relationships with hospitals, medical centers, and healthcare providers to strengthen its presence in the industry. One of Terumo's main divisions is cardiology. The company offers a wide range of products and services that can be used for the treatment of heart diseases. These include catheters, balloon pumps, and devices for heart-lung machines. Terumo has also developed unique technology that enables the use of heart implants and improves the quality of life for patients with heart diseases. Terumo also has a strong presence in oncology. The company offers a wide range of products and services that can be used for the diagnosis and treatment of cancer. These include catheters, needles, and devices for chemotherapy administration. Terumo has also developed unique technology that allows the direct delivery of drugs to cancer cells to improve treatment effectiveness. Terumo is also involved in the field of radiology. The company offers a wide range of products and services that can be used for the diagnosis and treatment of diseases and injuries, including X-ray and CT machines, as well as contrast agents. Terumo has also developed innovative technologies that improve the accuracy and efficiency of these devices to achieve better outcomes for patients. Terumo is also involved in the field of endoscopy. Here, the company offers a wide range of products and services that can be used for the diagnosis and treatment of digestive system disorders and other internal organ diseases. These include endoscopes, catheters, and mucosectomy devices. Furthermore, Terumo specializes in diabetes management. The company offers a wide range of products and services that can be used for monitoring and regulating blood sugar levels, including insulin pumps and continuous glucose monitoring systems. Terumo has also developed innovative technology that reduces the pain and complications experienced by diabetic patients. Lastly, Terumo is also involved in the field of blood management. The company offers a wide range of products and services that can be used for the diagnosis and treatment of blood disorders, including blood coagulation tests and blood transfusion devices. Terumo has also developed innovative technology that improves the effectiveness and safety of blood transfusions and reduces the risk of infections and other complications. Overall, Terumo is a leading force in the medical industry and offers a wide range of products and services that contribute to improving the health and well-being of people worldwide. Through continuous research and development, global marketing and distribution network, and a solid presence in various medical specialties, the company has a strong business model and positions itself for further growth and success in the future.

odotettu liikevaihto Terumo on 1,12 T JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Terumo on 135,10 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Terumo:n hinta-voitto-suhde (P/E) on tällä hetkellä 28,75. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Terumo-osakkeen arvostusta.

Terumo:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,46. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Terumo-osakkeen arvostuskennuslukuna.

Terumo:n Eulpool-laatuscore on 8/10.

Terumo:n ISIN on JP3546800008. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Terumo:n WKN on 867003. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Terumo:n ticker on 4543.T. Tämä pörssinoteeraus käytetään Terumo-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Terumo maksoi osinkoa 28,00 JPY . Tämä vastaa osingontuottoa noin 1,07 %. Tulevien 12 kuukauden aikana Terumo odotetaan maksavan osinkoa 51,60 JPY.

Terumo:n nykyinen osinkotuotto on 1,07 %.

Terumo maksaa osinkoa, joka jaetaan kuukausina , , , .

Terumo maksoi osinkoa joka vuosi viimeisten 36 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 51,60 JPY. Tämä vastaa osingontuottoa 1,97 %.

Terumo kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Terumo:sta päivältä määrässä 15 JPY, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Terumo jakoi 21,5 JPY osinkona.

Terumo:n osingot jaetaan valuutassa JPY.